OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Talwar on the Utility of Immunotherapy in Metastatic Urothelial Carcinoma

May 24th 2021

Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.

Dr. Powell on Managing Trastuzumab Deruxtecan–Induced ILD in HER2+ Breast Cancer

May 21st 2021

Charles Powell, MD, MBA, discusses managing fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Dr. Garg on Selecting Between Antiandrogen Agents in Nonmetastatic CRPC

May 21st 2021

Natasha Garg, DO, discusses selecting between antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Diamond on the Need to Integrate MRD Testing Into Clinical Trials in Multiple Myeloma

May 21st 2021

Benjamin Diamond, MD, discusses the need to integrate minimal residual disease testing into clinical trials in multiple myeloma.

Dr. Ramaswamy on Determining Treatment Courses in Metastatic HER2+ Breast Cancer

May 20th 2021

Bhuvaneswari Ramaswamy, MD, discusses determining treatment courses for individual patients with HER2-positive breast cancer.

Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple Myeloma

May 20th 2021

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Dr. Burgess on Future Directions With PARP Inhibitors in Prostate Cancer

May 20th 2021

Earle Burgess, MD, discusses future directions with PARP inhibitors in prostate cancer.

Dr. Johnson on the Rationale for Examining Chronic irAEs Associated With Anti-PD-1 Therapy in Melanoma

May 20th 2021

Douglas B. Johnson, MD, discusses the rationale for examining chronic immune-related adverse effects associated with anti–PD-1 therapy in patients with high-risk resected melanoma.

Dr. Niu on Selecting Between Selpercatinib and Pralsetinib in RET Fusion+ NSCLC

May 19th 2021

Jason Niu, MD, PhD, discusses considerations for selecting between selpercatinib and pralsetinib in RET fusion–positive non–small cell lung cancer.

Dr. Ramaswamy on the Potential for Adjuvant CDK4/6 Inhibition in HR+/HER2- Breast Cancer

May 19th 2021

Bhuvaneswari Ramaswamy, MD, discusses the potential utility of CDK4/6 inhibitors in the adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer.

Dr. Pellini on the Challenges of Using Topotecan as a Comparator Arm in Recurrent ES-SCLC

May 19th 2021

Bruna Pellini, MD, discusses the challenges of using topotecan as a comparator arm for second-line clinical trials in extensive-stage small cell lung cancer.

Dr. Monk on Guidelines for Maintenance PARP Inhibitors in Ovarian Cancer

May 19th 2021

Bradley J. Monk, MD, FACS, FACOG, highlights current guidelines for utilizing maintenance PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Socinski on the Evolving Paradigm of Targeted Therapy in Lung Cancer

May 18th 2021

Mark A. Socinski, MD, discusses the evolving paradigm of targeted therapy in lung cancer.

Dr. Hubbard on Utilizing Single-Agent Immunotherapy in MSI-H CRC

May 18th 2021

Joleen M. Hubbard, MD, discusses the potential for treatment with immunotherapy alone in patients with colorectal cancer.

Dr. Doroshow on the Importance of Modernizing Clinical Trials After COVID-19

May 18th 2021

James H. Doroshow, MD, discusses the importance of modernizing clinical trials in the post–COVID-19 era.

Dr. Ward on Adding Systemic Therapy to Radiation Therapy in Prostate Cancer

May 18th 2021

Matthew C. Ward, MD, discusses when to consider adding systemic therapy to radiation therapy in prostate cancer.

Dr. Lower on the Impact of Tucatinib on HER2+ Breast Cancer

May 17th 2021

Elyse Lower, MD, discusses the impact of tucatinib on the treatment of patients with HER2-positive breast cancer.

Dr. Yohe on the Potential to Target RAS Mutations in Pediatric Cancers

May 17th 2021

Marielle E. Yohe, MD, PhD, discusses the potential utility of targeting RAS mutations in pediatric cancers.

Dr. Rini on the Results of an Exploratory Analysis of the IMmotion151 Trial in mRCC

May 17th 2021

Brian I. Rini, MD, discusses the results of an exploratory analysis of the phase 3 IMmotion151 trial in metastatic renal cell carcinoma.

Dr. Tap on the Effects of the COVID-19 Pandemic on Sarcoma

May 17th 2021

William D. Tap, MD, discusses the effects of the COVID-19 pandemic on the treatment of patients with sarcoma.